Evidence map›Paper›PMID 36551170›Full record

ArticleBiomolecules2022

SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy.

Kevin C Chan, Yi Song, Zheng Xu, Chun Shang, Ruhong Zhou

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Variant-Specific Viral Kinetics in Acute COVID-19.The Journal of infectious diseases · 2023
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Kevin C ChanInstitute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.ORCID 0000-0002-3705-1835
Yi SongInstitute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
Zheng XuBirenTech Research, Shanghai 201112, China.ORCID 0000-0003-0113-0010
Chun ShangInstitute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
Ruhong ZhouInstitute of Quantitative Biology, College of Life Sciences, Zhejiang University, Hangzhou 310058, China.
Shanghai Advanced Research Institute · CNZhejiang University · CN

Funding

BirenTech Research BR-ZJU-SIAS-001National Independent Innovation Demonstration Zone Shanghai Zhangjiang Major Projects ZJZX2020014National Key Research and Development Program of China 2021YFA1201201National Key Research and Development Program of China 2021YFF1200404National Natural Science Foundation of China U1967217Starry Night Science Fund of Zhejiang University Shanghai Institute for Advanced Study SN-ZJU-SIAS-003W. M. Keck Foundation 2019-2022
6 · The paper itself

Abstract

Since its first appearance in April 2021, B.1.617.2, also termed variant Delta, catalyzed one major worldwide wave dominating the second year of coronavirus disease 2019 (COVID-19) pandemic. Despite its quick disappearance worldwide, the strong virulence caused by a few point mutations remains an unsolved problem largely. Along with the other two sublineages, the Delta variant harbors an accumulation of Spike protein mutations, including the previously identified L452R, E484Q, and the newly emerged T478K on its receptor binding domain (RBD). We used molecular dynamics (MD) simulations, in combination with free energy perturbation (FEP) calculations, to examine the effects of two combinative mutation sets, L452R + E484Q and L452R + T478K. Our dynamic trajectories reveal an enhancement in binding affinity between mutated RBD and the common receptor protein angiotensin converting enzyme 2 (ACE2) through a net increase in the buried molecular surface area of the binary complex. This enhanced binding, mediated through Gln493, sets the same stage for all three sublineages due to the presence of L452R mutation. The other mutation component, E484Q or T478K, was found to impact the RBD-ACE2 binding and help the variant to evade several monoclonal antibodies (mAbs) in a distinct manner. Especially for L452R + T478K, synergies between mutations are mediated through a complex residual and water interaction network and further enhance its binding to ACE2. Taking together, this study demonstrates that new variants of SARS-CoV-2 accomplish both "attack" (infection) and "defense" (antibody neutralization escape) with the same "polished sword" (mutated Spike RBD).

Indexed as

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAllosteric RegulationAntibodies, MonoclonalHumansPoint MutationProtein BindingProtein DomainsVirulenceAngiotensin-Converting Enzyme 2Antibodies, MonoclonalSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2allosterybinding free energyfree energy perturbationmolecular dynamics simulationsprotein-protein interactionsSARS-CoV-2SARS-CoV-2 variants

Identifiers

PMID36551170
PMCPMC9775976
OpenAlexW4309845786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.